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 Letter to the Editor 
 The National Center for Complementary and Integrative 
Health (NCCIH) defines mind-body medicine as a variety of tech-
niques designed ‘to use the mind to affect physical functioning and 
promote health’  [4] . The integrative body-mind-spirit (I-BMS) 
model is an integrative approach derived from Traditional Chinese 
Medicine, Confucianism, and Daoism  [5] . Core beliefs of the I-
BMS model include (a) the interconnectedness of body, mind, and 
spirit, (b) the importance of spirituality as a domain of human ex-
istence, (c) the need to reach beyond symptom reduction to attain 
growth and transformative changes and (d) the dual goal of healing 
and capacity building  [6] . Numerous studies have supported its 
effectiveness in enhancing the quality of life of various clinical pop-
ulations  [5–7] . This study attempted to establish the clinical effec-
tiveness of the I-BMS model on sleep disturbances, mood, and in-
flammatory responses. We hypothesize that compared to the wait-
list control (WLC) condition participants in the immediate I-BMS 
condition will experience greater improvement in depression and 
sleep disturbances and a reduction in IL-6 levels.
 The current study was a randomized, WLC trial (http://www.
hkclinicaltrials.com/; trial No. HKCTR-1929; ethical ref. No. UW 
13-485). A total of 1,002 Hong Kong Chinese adults from the com-
munity completed online a battery of self-administered scales, in-
cluding the Center for Epidemiologic Studies Depression Scale 
(CESD), the Pittsburgh Sleep Quality Index (PSQI), and other 
psychosocial measures. Individuals who were Chinese adults with 
mild to moderate depression (34 ≥ CESD  ≥ 10  [8] ) and insomnia 
 Poor sleep quality is a diagnostic criterion in major depressive 
disorder  [1] . Individuals with depression tend to suffer from sleep 
disturbances, including difficulty in initiating or maintaining 
asleep, early morning awakening, unrefreshing sleep, and hyper-
somnia. A growing body of research also suggests that inflamma-
tory cytokines, such as interleukin-6 (IL-6), are associated with the 
manifestation of depression and sleep disturbances  [2, 3] . Al-
though empirical findings regarding the direction of association 
among depression, sleep disturbances, and IL-6 are not conclusive 
 [2, 3] , their association underscores the interconnectivity between 
the body and the mind.
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 Table 1.  Treatment outcomes for sleep, depression, and IL-6 measures
Mean ± SD at 3 time points Between- and within-group Cohen’s d (95% CI)
pretreatment posttreatment 3-month follow-up pr e- to posttreatment pretreatment to 3-month 
follow-up
CESD 0.37 (0.08 to 0.66)a 0.44 (0.15 to 0.73)a
I-BMS 21.79 ± 6.96 15.24 ± 8.52 13.98 ± 7.44 0.84 (0.42 to 1.27)b 1.08 (0.65 to 1.52)b
Control 20.68 ± 6.16 18.21 ± 7.66 17.22 ± 7.39 0.36 (–0.05 to 0.77)c 0.47 (0.10 to 0.92)c
PSQI global 0.30 (0.01 to 0.58)a 0.32 (0.03 to 0.61)a
I-BMS 13.54 ± 2.80 11.08 ± 3.79 10.55 ± 3.78 0.74 (0.32 to 1.16)b 0.90 (0.47 to 1.33)b
Control 13.32 ± 2.89 12.06 ± 2.77 11.78 ± 3 .84 0.45 (0.03 to 0.86)c 0.45 (0.04 to 0.87)c
IL-6 0.46 (0.17 to 0.75)a –0.06 (–0.34 to 0.23)a
I-BMS 1.49 ± 1.95 1.24 ± 1.70 1.60 ± 2.93 0.14 (–0.27 to 0.55)b
Control 1.75 ± 2.88 2.67 ± 4.04 1.46 ± 2.08 –0.26 (–0.67 to 0.15) c
 Baseline, posttreatment, and follow-up data are presented for each group along with change scores and within-group effect sizes. 
Intention-to-treat sample: I-BMS n = 92, WLC n = 93.
a Between-group effect size. b Within-group effect size of I-BMS. c Within-group effect size of WLC. For IL-6, a significant between-
group effect was only attained at posttreatment, but not at the 3-month follow-up. Thus, the within-group effect sizes of IL-6 are not 
calculated at the comparison between T0 and T2 in both groups.
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(PSQI >5  [9] ) were recruited. Exclusion criteria included self-re-
ported comorbidity with psychotic conditions such as schizo-
phrenia and previous experience with I-BMS. Of the 533 eligible 
participants, 200 were randomly selected based on a computer-
generated list of random numbers because of resource limitations 
in intervention. Fifteen participants did not provide written con-
sent, and the remaining 185 participants were randomly assigned 
to either an immediate I-BMS group (n = 92) or a 6-month WLC 
condition (n = 93). The I-BMS group consisted of eight 3-hour 
weekly group sessions with culturally relevant mind-body exer-
cises, mindfulness practices, self-reflection via experimental ac-
tivities, and group discussion and sharing. All measures, including 
the plasma IL-6 levels via blood test, were collected at baseline 
(T 0 ), immediately after the intervention (T 1 ), and 3 months after 
the intervention (T 2 ). The flowchart of the trial is presented in 
 figure 1 .
 t tests and χ 2 tests were used to compare the baseline character-
istics of participants in the I-BMS versus WLC groups. Intention-
Included in intention-to-treat analysis
(n = 92)
Assessed for eligibility 
(n = 553)
Randomized
(n = 185)
Randomly selected potential participants
(n = 200)
Excluded (n = 15)
Failed to provide written consent form
Allocated to I-BMS group
(n = 92)
Allocated to WLC group
(n = 93)
Postassessment
(8 weeks)
Complete assessment (n = 73)
Withdrawal from study (n = 20)
• No reason provided (n = 14)
• Refusal to draw blood (n = 3)
• Busy with other duties (n = 2)
• Away from Hong Kong (n = 1) 
Complete assessment (n = 68)
Withdrawal from study (n = 24)
• No reason provided (n = 13)
• Not interested anymore (n = 1)
• Accidental physical injury (n = 1)
• Refusal to draw blood (n = 3)
• Distance of the center (n = 2)
• Busy with other duties (n = 4)
Included in intention-to-treat analysis
(n = 93)
Complete assessment (n = 69)
Lost to follow-up (n = 4)
Complete assessment (n = 57)
Lost to follow-up (n = 11)
3-month follow-up
 Fig. 1. Flowchart of the randomized controlled trial of I-BMS on depression and sleep disturbances. 
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to-treat analysis was conducted to evaluate treatment effective-
ness. Missing data in the I-BMS group were imputed by last obser-
vation score and assuming no improvement. The group mean was 
used to substitute missing values for participants from the WLC 
group at T 1 and T 2 . The effects of I-BMS intervention were inves-
tigated by ANCOVAs with age, gender, and baseline scores as co-
variates. Cohen’s d s were calculated as effect sizes. Forward linear 
regression analyses of subsamples were performed to examine the 
effects of I-BMS on changes of PSQI, CESD (minus the item on 
sleep quality), and IL-6 at T 1 and T 2 for participants with baseline 
CESD  ≥ 16, indicating significant depressive symptoms  [8] . The 
change of each outcome (T 0 – T 1 ) was entered as the dependent 
variable, whereas the treatment conditions (I-BMS vs. WLC) were 
the predicting variables, with adjustment for age, gender, baseline 
scores, and the other two key outcomes.
 In this study, 75.1% were female, with a mean age of 55.28 ± 
9.83 years. 58.4% had secondary level education, and 72.4% were 
married or cohabited. A majority (93.7%) of participants reported 
insomnia that lasted more than 1 year, with 61.1% reporting more 
than 3 years. Baseline characteristics, including the scores for key 
outcomes, were comparable between the two groups (I-BMS vs. 
WLC) and between dropouts and completers.
 Table 1 displays the descriptive statistics and the within- and 
between-group effect sizes of the two groups at the three time 
points. The remission rate of depression (a reduction in CES-D 
score to <16  [8] ) was significantly greater in the I-BMS group than 
in the WLC group at T 1 [45% (23/51) vs. 21% (11/52), differ-
ence = 24%, 95% CI: 5.8–40.1%; p = 0.01] and T 2 [57% (23/40) vs. 
28% (13/46), difference = 29%, 95% CI: 8–47%; p = 0.004]. ANCO-
VAs yielded significant group effects on overall sleep quality
(F 1, 180 = 2.06, p = 0.016), depression (F 1, 180 = 13.49, p < 0.001), and 
IL-6 (F 1, 180 = 9.02, p = 0.003) at T 1 , favoring the intervention 
group. The effects on overall sleep quality (F 1, 180 = 10.03, p = 0.002) 
and depression (F 1, 180 = 13.39, p < 0.001) but not IL-6 (F 1, 180 = 
5.50, p = 0.225) were sustained at T 2 . The effect sizes were small to 
medium (Cohen’s  d ranging from 0.30 to 0.46). Within-group ef-
fect sizes indicate medium to large decreases in PSQI and CESD in 
the I-BMS group at both T 1 and T 2 . As for IL-6, a medium within-
group effect size was shown at T 1 in the I-BMS group.
 Results of regression at both T 1 (n = 103) and T 2 (n = 83) show 
that I-BMS intervention (WLC = 1; I-BMS = 2) was independent-
ly associated with an improvement of PSQI at T 2 but not at T 1 (T 1 : 
B = 0.98, p = 0.12; T 2 : B = 1.66, p = 0.02). The effect of I-BMS in-
tervention on CESD was found to be significant at T 1 and T 2 (T 1 : 
B = 5.499, p < 0.001; T 2 : B = 4.05, p = 0.04), but for IL-6 the ad-
justed treatment effects were only found at T 1 (T 1 : B = 2.04, p = 
0.01; T 2 : B = –0.34, p = 0.11).
 The current study is the first attempt to test the effect of I-BMS 
on inflammatory responses alongside other physical (sleep) and 
mental (depression) health indicators. Our findings indicate the 
effectiveness of I-BMS in facilitating sleep and alleviating depres-
sion, as well as reducing IL-6 levels (at T 1 only). In line with previ-
ous findings, the current results support the interconnectivity be-
tween the body and the mind  [2, 3] , as well as the efficacy of I-BMS 
in relieving distress in these two reciprocating faculties of human 
existence  [5–7] . The lack of effect of IL-6 at T 2 could be due to nor-
mal fluctuation and variations of plasma IL-6 concentration of the 
participants.
 The current study has several limitations. First, the lack of an 
active control group compromised the validation of effectiveness. 
Waitlist control design is limited in detecting specific therapeutic 
factors that are distinctive from expectation and placebo effects. 
Future studies may adopt mind-body education or physical exer-
cise programs as active control for examining the therapeutic effect 
of I-BMS. Second, due to the lack of a standardized diagnostic in-
terview, caution should be taken when generalizing the current 
findings to a clinical sample. Moreover, insomnia symptoms were 
collected mainly via subjective reports. Future studies may supple-
ment subjective reports with objective measures, including actig-
raphy and polysomnography  [10] . Currently, there is not sufficient 
empirical support for the causal direction of the relationships 
among sleep, mood, and IL-6  [2, 3] . Further intervention and lon-
gitudinal studies are needed to provide information on this mind-
body relationship by investigating the mediating pathways in the 
improvement of these indicators.
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